Hummingbird Bioscience https://validator.w3.org/feed/docs/rss2.html News – 2017 Home Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards News About Us Publications & Posters Publications & Posters – 2017 Publications & Posters – 2018 Publications & Posters – 2019 Publications & Posters – 2020 Publications & Posters – 2021 Publications & Posters – 2022 Publications & Posters – 2023 Publications & Posters – 2024 Publications & Posters – 2025 News – 2025 News – 2024 News – 2023 News – 2022 News – 2021 News – 2020 Hummingbird Bioscience Closes US$25 Million Investment With Series B Extension News – 2019 News – 2018 Patients Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies ADC Platform Hummingbird Bioscience Appoints Dipti Thakkar, PhD, as Chief Operating Officer Hummingbird Bioscience Licenses Novel Antibodies to Immunome HMBD-002 Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics Pipeline HMBD-001 Partnering Hummingbird Bioscience Awarded $13.1 Million Grant by the Cancer Prevention and Research Institute of Texas (CPRIT) Privacy Policy Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-Driven Precision Medicine to Accelerate Clinical Development of HMBD-001 in HER3-Driven Cancers Including NRG1 Fusions Hummingbird Bioscience Presents Pre-Clinical Data on its Next-Generation BCMA-TACI Dual-Specific T Cell Engager at 2021 AACR Annual Meeting Hummingbird Bioscience Raises US$125 Million in Series C Financing Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society Of Clinical Oncology (ASCO) 2021 Annual Meeting Hummingbird Bioscience and Novogene Enter into Strategic Partnership to Expand Precision Medicine Testing for Individuals with NRG1 Fusion-Driven Cancers in China Hummingbird Bioscience to Speak at 2021 Virtual Symposium: “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors View Replay: 3rd Annual Virtual VISTA Symposium Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept Join Us Cancer Research, Volume 77, Issue 13, AACR Journals: HMBD-002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models Cancer Research, Volume 77, Issue 13 Supplement, AACR Journals: HMBD-001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of ErbB3+ solid tumors Cancer Research, Volume 78, Issue 13, Supplement, AACR Journals: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD-002, a novel anti-VISTA neutralizing antibody HMBD-501